Lipid Nanoparticles in mRNA Vaccine Delivery

How do lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccine antigens?

Lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines by encapsulating the mRNA through electrostatic and hydrogen bonding interactions, facilitating cellular uptake via endocytosis, and releasing the mRNA into the cytoplasm when ionizable lipids protonate in acidic endosomes and disrupt the endosomal membrane to enable translation.

Abstract

Lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines through a coordinated physicochemical and biological process. LNPs composed of ionizable lipids, helper lipids, cholesterol, and PEG-lipids form 50-85 nm particles that encapsulate mRNA via electrostatic interactions and hydrogen bonding. Following intramuscular administration, LNPs are taken up by muscle-resident immune cells through endocytosis, with >10% of myeloid and lymphoid cells successfully transduced. The critical delivery step occurs when ionizable lipids protonate in acidic endosomes (pH ~5-6), triggering ion pairing with endosomal phospholipids that disrupts membranes and releases mRNA into the cytoplasm. Nucleoside modifications such as m1ψ reduce innate immune recognition of the mRNA cargo, while optimized formulations achieve 93-95% encapsulation efficiency and mRNA detectability for 14-28 days post-vaccination in humans.

Beyond mRNA delivery, LNPs function as intrinsic adjuvants by triggering rapid neutrophil and dendritic cell recruitment within 24 hours and inducing IL-6 production critical for germinal center responses. This dual functionality produces potent immunogenicity, with optimized formulations achieving 10-fold higher neutralizing titers than standard LNPs and protective immunity at doses as low as 0.25 µg. Rational lipid design enables independent control of delivery efficiency, tissue targeting, immune activation, and stability: the C24 formulation reduces off-target liver expression 6-fold while maintaining potency, adjuvant lipidoids provide TLR7/8 activation, and specific formulations remain stable at 4°C for at least 19 days. These mechanisms collectively explain the exceptional clinical efficacy of LNP-mRNA SARS-CoV-2 vaccines.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects related to the research question.

Results

Characteristics of Included Studies

All 10 studies investigated lipid nanoparticle delivery systems for nucleoside-modified mRNA encoding SARS-CoV-2 spike protein antigens. Seven studies had full text available, while three were abstract-only. The studies employed diverse approaches including novel lipid development, structural characterization, immunogenicity testing in animal models, and clinical pharmacokinetic analysis in humans.

LNP Composition and Formulation Design

LNP formulations for SARS-CoV-2 mRNA delivery consist of four core lipid components: ionizable lipids, helper lipids, cholesterol, and PEG-lipids. The ionizable lipid component is critical for mRNA complexing and pH-dependent release.

mRNA Cargo Characteristics

The nucleoside-modified mRNA cargo encoded the SARS-CoV-2 spike protein with specific structural modifications. The target antigens included full-length spike protein with deleted furin cleavage site.

Cellular Uptake and Delivery Mechanisms

LNPs deliver mRNA through a multi-step process involving cellular uptake, endosomal escape, and cytoplasmic release. The ionizable lipids play a central role in pH-dependent delivery.

Uptake pathways and cell types: Muscle-resident myeloid and lymphoid cells were directly transduced, with >10% of these cells successfully receiving mRNA.

Endosomal escape mechanism: The cellular uptake occurred via endocytosis. Following endocytosis, ionizable lipids became protonated in the acidic endosomal environment. This protonation triggered ion pairing with endosomal phospholipids to open the endosomal membrane.

Delivery Efficiency and Protein Expression

Quantitative delivery efficiency varied across formulations, with several showing superior performance compared to standard formulations.

Protein expression levels: The C24 LNP showed 2-fold higher luciferase expression at injection sites compared to MC3 at both high and low doses.

Dose-response relationships: The C24 LNP was effective at very low doses, with protection against SARS-CoV-2 occurring at 0.25 µg prime/boost.

Biodistribution Patterns

Following intramuscular administration, LNPs demonstrated specific biodistribution kinetics with varying degrees of systemic exposure.

Distribution timeline in humans: In a clinical study of 19 subjects receiving Moderna SPIKEVAX, both mRNA and ionizable lipid peaked in blood 1-2 days post-vaccination, remaining detectable for 14-28 days post-vaccination in most subjects.

Tissue targeting: Primary target tissues included skeletal muscle at the injection site and draining lymph nodes.

Immune Activation and Adjuvant Properties

Beyond mRNA delivery, LNPs demonstrated intrinsic adjuvant activity contributing to robust immune responses.

Innate immune activation: LNP formulations triggered strong innate immune responses through multiple mechanisms, inducing cytokine production critical for T follicular helper cell differentiation.

TLR activation: The C12-TLRa adjuvant lipidoid conferred Toll-like receptor 7/8-agonistic activity to LNPs.

Synthesis

The mechanisms by which lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines involve an integrated series of physicochemical and biological processes. The delivery cascade initiates with formulation design, where ionizable lipids complex with negatively charged mRNA, facilitating cellular uptake and subsequent translation into spike protein antigen. Beyond mRNA delivery, LNPs serve as adjuvants, enhancing immune responses and achieving protection at very low doses. This highlights the potential of rational lipid design in optimizing mRNA vaccine performance.